News

Dosing has begun for healthy volunteers in a Phase 1 clinical trial of AL101, which has the potential to treat neurodegenerative disorders such as Parkinson’s, Alector recently announced. The randomized, placebo-controlled trial (NCT04111666) is testing the safety, tolerability, pharmacokinetics (how the compound moves throughout the body), and pharmacodynamics…

A bioactive agent called baicalin prevented neurodegeneration of Parkinson’s disease in rats by protecting against oxidative stress and neuronal death, according to a recent study. The results, “Neuroprotective effect and mechanism of baicalin on Parkinson’s disease model induced by 6-OHDA,” were published recently in the journal Neuropsychiatric Disease…

A compound that affects some of the same receptors in the brain as cannabis could help reduce dyskinesia — involuntary muscle movement — that develops following levodopa treatment in Parkinson’s disease, a new study done in mice suggests. The mice were treated with HU-308, an…

Cannabinoid-based formulations in development at GB Sciences were able to ease behavioral symptoms linked to the loss of dopamine producing-nerve cells — a hallmark of Parkinson’s — in a mouse model of the disease, the company said. GB Sciences will use these early results to support an…

A once-a-week multi-modal exercise program can improve and preserve motor function and cognition in Parkinson’s patients, according to a recent study. Results of the study were presented in a session, “Can a Weekly Multi-Modal Exercise Class Preserve Motor and Non-Motor Function in Parkinson’s?” at The Physiological Society‘s recent early…

The U.S. Food and Drug Administration has accepted Sunovion‘s resubmitted new drug application (NDA) for APL-130277, an oral apomorphine therapy for treating off episodes in Parkinson’s disease. The FDA had asked for additional information regarding APL-130277, following the first NDA in mid-2018. A…

Patient treatment has been completed in a Phase 1/2 clinical trial testing cerebral dopamine neurotrophic factor (CDNF) for Parkinson’s disease, Herantis Pharma has announced. The trial (NCT03295786) is testing the safety and tolerability of CDNF in 17 patients with advanced Parkinson’s disease. Of these patients,…

A type of computational analysis that works to analyze typing patterns may help in detecting motor signs of Parkinson’s disease at early stages, the researchers who developed the analysis report. This new method, which appeared to allow researchers to discriminate between people with early Parkinson’s and those without the disease,…

The Feinstein Institutes for Medical Research announced that the U.S. Food and Drug Administration (FDA) has approved an imaging compound its researchers developed as a diagnostic tool for people with suspected parkinsonian syndromes, including Parkinson’s disease. Fluorodopa F18 (FDOPA) is an injectable compound used during a PET…

Parkinson’s News Today keeps you up-to-date with research into Parkinson’s disease as it emerges. We brought you daily coverage of experiments into the basic biology of Parkinson’s, results of clinical and pre-clinical trials, and key findings from Parkinson’s research around the globe. We look forward to bringing more such…